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Bullous pemphigoid (BP) is a chronic autoinflam-
matory, blistering disease typically affecting the
elderly. It is the most common disorder within the
pemphigoid group and represents the most frequent
autoimmune blistering disease in general.1,2 The
etiopathogenesis involves the induction of an
inflammatory cascade that is hypothesized to include
many triggering factors, one of which includes
infections.2 Here we present a man with a history
of stable BP and subsequent severe flaring of his
disease after contracting hand, foot, and mouth
disease (HFMD). We also discuss rituximab as an
adequate therapy in treating refractory BP.CASE REPORT
A 56-year-old white man with a history of asthma,
chronic renal failure, and stable BP presented with
complaints of worsening pruritic vesicles over the
course of 2 months. These lesions developed
2 months after contracting a severe case of HFMD
diagnosed by his primary care physician. His diag-
nosis was based on his high fevers and severe
blistering on his hands, feet, and mouth, and he
was confined to bed for 2 weeks amid a coxsack-
ievirus A6 (CVA6) breakout in the summer of 2012.
His primary care physician prescribed prednisone,
40 to 60 mg orally daily, which resulted in mild-to-
moderate control of his blisters.
Before his CVA6 infection, his BP was in complete
remission on a regimen of prednisone, 10 mg orally
every other day. He presented to our dermatology
clinic with his posteCVA6-induced flare, at which
time his physical examination found 40% to 50% of
his body surface area covered with tense bullae,
erosions, and crust located on his face, neck, chest,the Department of Dermatology, University of Texas Medical
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555-0783. E-mail: mgwilker@utmb.edu.abdomen, back, buttocks, genitalia, and bilateral
upper and lower extremities, with sparing of the oral
mucosa (Fig 1, A and B). In addition, his laboratory,
histopathology, and direct immunofluorescence
findings all supported a diagnosis of BP at that
time. Results of a paraneoplastic pemphigus panel
were normal, and the pemphigoid panel found an
elevated BP 230 IgG antibody level (106 U; normal
\9 U) and slightly elevated BP 180 IgG antibody
level (25 U; normal\9 U; ARUP Laboratories, Salt
Lake City, Utah).
He was prescribed prednisone, 60 mg orally daily,
doxycycline, 100 mg orally twice a day, and myco-
phenolate mofetil, 1500 mg tablet orally daily with
repeated attempts to taper prednisone. However,
because of frequent flaring and inability to taper
prednisone over the course of 6 months, we initiated
rituximab, 1000 mg intravenously on days 1 and 15,
followed by 500 mg/m2 intravenously monthly for 2
doses. With this regimen, his prednisone was
tapered down to 10 mg and mycophenolate mofetil
down to 500mg. In total, the patient received 4 doses
of rituximab infusions (375 mg/m2 per infusion).
With each infusion, he experienced acute onset of
pruritus followed by significant clearing of lesions
over several days. Complete metabolic panel,
complete blood count, and pemphigoid panels
were followed up with closely. He currently remains
asymptomatic with downward trending BP titers
with a maintenance regimen of prednisone, 10-mgJAAD Case Reports 2016;2:7-9.
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Fig 1. Scattered erosions, crusts and tense bullae on the right superior anterolateral chest and
axilla (A) and left upper arm and shoulder (B) 4 months after contracting HFMD.
Fig 2. Postinflammatory hypopigmentation with patches
of erythema and scattered milia on the left arm 6 months
after initiating rituximab.
JAAD CASE REPORTS
JANUARY 2016
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tablet orally twice a day, and doxycycline, 100-mg
tablet orally daily (Figs 2 and 3).
DISCUSSION
BP is a chronic autoimmune disorder that is
clinically identified by widespread tense bullae,
erosions, or persistent pruritic urticarial lesions.2
These bullae are caused by antibodies against
hemidesmosomal antigens, particularly BP antigen
1 (BP 230) and BP antigen 2 (BP 180), resulting in a
characteristic autoantibody deposition at the
epidermal basement membrane.2,3 BP incidence is
estimated between 4.5 and 22 new cases per 1
million per year in central Europe.4 Yet, with more
advanced ways to diagnose this condition, BP
incidence appears to be increasing.
BP etiopathogenesis is not currently well under-
stood. Overall, genetic predisposition and inducing
factors are known to lead to the onset and course
of BP. In fact, the human leukocyte antigen
HLA-DQB1*0301 gene is reported to be a major
genetic predisposing factor for BP.1,2 In addition,
many physical triggers are documented to induce BP
including drugs, radiotherapy, ultraviolet light,
thermal and electrical burns, and even surgical
procedures.2
Infectious agents are triggers for autoimmune
conditions, including blistering diseases. Micro-
organisms have been identified in patients with BP
and pemphigus vulgaris, including human herpes
viruses, hepatitis B and C viruses, Helicobacter
pylori, and Toxoplasma gondii.2 A recent study
reported a relationship between pemphigus vulgaris
and CV but was unable to detect the viral genome in
skin of affected patients.5 Although there was an
elevated CV-IgG positivity ratio, it proved to not
be statistically significant.5 In current literature,
HFMD-induced BP exacerbation has not been
reported.HFMD is a clinical syndrome characterized by a
maculopapular or vesicular viral exanthem of the
hands, feet, and oral mucosa. Typically, it is caused
by CVA16 and enterovirus 71, causing an acute
self-resolving viral disease most commonly in
children.3 However, CVA6 outbreaks were reported
by the Centers for Disease Control and Prevention in
the United States between 2011 and 2012.3 The
reported cases were more severe resulting in higher
fevers, extensive cutaneous eruptions, and hospital-
izations for dehydration and severe pain in adults
and children.3 This outbreak was around the same
time that our patient had contracted HFMD.
BP’s chronic, debilitating nature results in high
morbidity and mortality if not adequately treated.
Treatment goals include decreasing blister formation
and pruritus, promoting healing of blisters and
erosions, and improving quality of life. Systemic
prednisone is the first-line therapy for BP.
Azathioprine, methotrexate, cyclophosphamide,
and mycophenolate mofetil are corticosteroid-
sparing agents and are sometimes used as adjuvant
therapy. In addition, anti-inflammatory drugs
including tetracyclines, nicotinamide, or dapsone
Fig 3. Patient’s IgG BP antibody level (units) throughout course of treatment. Significant
downward trending of his BP titers is noted. M, Months.
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or in combination with corticosteroids in some
patients.6 The response to treatment depends on
the extent and severity of the disease, patient
age, existence of comorbidities, and previous
treatments.7 For cases refractory to conventional
therapies, rituximab, an anti-CD20 monoclonal
antibody, has been used off label.
Rituximab depletes B cells in the periphery and
affects T cells, ultimately resulting in immuno-
suppression by decreasing BP’s antibodies against
the recipient’s hemidesmosomes,7 thereby
decreasing BP’s autoimmune nature. In addition,
there is evidence that there are structural and
functional differences between normal B cells, ma-
lignant B cells, and B cells present in patients with
autoimmune diseases.7 This finding may explain the
improvement of our patient’s BP without worsening
of his CVA6 infection. Nonetheless, future studies are
required to determine specific dosing, effectiveness,
and safety of using this novel agent to treat BP,
as associations with increased infection and
cardiotoxicity have been reported.7 Our patient
had an impressive response to rituximab, afterexperiencing disease recalcitrance with other treat-
ment modalities and has not exhibited adverse
effects to date.
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